QIAGEN Supports Research During Bundibugyo Ebolavirus Outbreak

QIAGEN is supporting infectious disease research and surveillance efforts during the Bundibugyo ebolavirus outbreak by providing molecular research technologies for laboratories studying the virus. The company has made research-use-only (RUO) QIAcuity digital PCR assays available to target the NP and VP35 regions of Bundibugyo ebolavirus.

Targeted Molecular Research

The custom assays are designed to detect specific genetic regions of Bundibugyo ebolavirus and can be integrated into existing QIAcuity digital PCR workflows. Initial sequence analysis reported by QIAGEN showed no mismatches against the published outbreak sequences reviewed by the company.

Supporting Genomic Surveillance

QIAGEN is also making QIAseq sequencing panels and sample-preparation and molecular workflow solutions available to support nucleic-acid processing, next-generation sequencing and genomic research activities.

Research Portfolio

1. Research-use-only QIAcuity digital PCR assays
2. Assays targeting NP and VP35 regions
3. QIAseq sequencing panels
4. Sample-preparation solutions
5. Molecular workflow kits
6. Support for genomic research and surveillance

Potential Research Areas

1. Infectious disease research
2. Viral genome analysis
3. Molecular surveillance
4. Digital PCR research
5. Next-generation sequencing
6. Wastewater surveillance
7. Outbreak genomic monitoring

Why It Matters

The availability of adaptable molecular research tools can help laboratories study emerging pathogen sequences and incorporate targeted assays into existing research workflows. QIAGEN's technologies provide researchers with tools to study Bundibugyo ebolavirus and support genomic surveillance activities during the outbreak. The assays are for research use only and are not intended for diagnostic procedures.